Project Grant HT94252410343
Award Date
9/30/24
Completion Date
8/31/27
Dollars Obligated
$817K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
The University of South Florida (USF) was awarded a $409,064 Project Grant by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct a "MULTIOMIC EVALUATION OF OVARIAN CANCER RESPONSES TO HEATED INTRAPERITONEAL CHEMOTHERAPY HIPEC". This 3-year award, with a performance period from September 30, 2024 to August 31, 2027, will support research to evaluate the use of multiomics analysis to better understand how ovarian cancer...
This $1,144,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Oklahoma Health Sciences Center to develop a drug targeting ORP4 as a precision treatment for ovarian cancer. The research aims to transform healthcare for military service members, veterans, and the broader public through innovative investigations spanning basic, applied, and translational domains....
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
This federal Project Grant award of $1,598,801.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel for the treatment of recurrent platinum-resistant ovarian cancer. The study is being conducted by the Dana-Farber Cancer Institute, Inc., a renowned non-profit cancer research and treatment center in Boston, Massachusetts. The award period runs from July 1, 2025...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
This Project Grant award of $508,747.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports the "THE OVARIAN CANCER OBSERVATORY: PREVENTION, IMPACT, AND LEARNING FROM OPPORTUNISTIC SALPINGECTOMY" research project conducted by the Provincial Health Services Authority (operating as BC Cancer) in Canada. Through this multi-year (Sep 1, 2023 - Aug 31, 2027) grant, BC Cancer will perform biomedical research to develop...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The Department of Defense's Defense Health Agency awarded a $1,067,418 Project Grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for the federal grant program "Military Medical Research and Development" (CFDA 12.420). The grant, titled "ACTIVATING GASDERMIN PORES TO INDUCE PYROPTOSIS AND ANTITUMOR IMMUNITY IN OVARIAN CANCERS," will fund research to investigate methods of inducing pyroptosis and enhancing antitumor immunity for the...
This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...